Kurzporträt
Umsatz nach Geschäftsbereich
USD in Millionen | 2022 | Gewichtung | 2023 | Gewichtung | Delta |
---|---|---|---|---|---|
Innovative Medicines
100,0
%
| 10 | 100,0 % | 0 | 100,0 % | -96.60% |
Umsatz je Region
USD in Millionen | 2022 | Gewichtung | 2023 | Gewichtung | Delta |
---|---|---|---|---|---|
United States
100,0
%
| 10 | 100,0 % | 0 | 100,0 % | -96.60% |
Manager
Manager | Titel | Alter | Seit |
---|---|---|---|
Sanjay Shukla
CEO | Chief Executive Officer | 52 | 30.03.16 |
Jill Broadfoot
DFI | Director of Finance/CFO | 63 | 30.07.18 |
Lisa Carey
CTO | Chief Tech/Sci/R&D Officer | - | 01.06.15 |
Ashlee Dunston
IRC | Investor Relations Contact | - | 01.04.20 |
Peter Villiger
PRN | Corporate Officer/Principal | - | 01.05.16 |
Human Resources Officer | - | 24.12.21 | |
General Counsel | - | 06.10.21 | |
Leslie Nangle
PRN | Corporate Officer/Principal | - | - |
Nancy Krueger
LAW | General Counsel | 56 | 01.10.14 |
Andrew B. Cubitt
PRN | Corporate Officer/Principal | - | 01.09.11 |
Aufsichtsräte
Aufsichtsräte | Titel | Alter | Seit |
---|---|---|---|
Paul Schimmel
FOU | Founder | 83 | 08.09.05 |
Tim Coughlin
CHM | Chairman | 57 | 10.04.17 |
John Clarke
BRD | Director/Board Member | 70 | 01.09.05 |
Sara Zaknoen
BRD | Director/Board Member | 65 | 25.05.21 |
Sanjay Shukla
CEO | Chief Executive Officer | 52 | 30.03.16 |
Jane Gross
BRD | Director/Board Member | 67 | 28.06.19 |
Svetlana Lucas
BRD | Director/Board Member | 52 | 28.06.19 |
Anteilsklasse
Vote | Menge | Streubesitz | Konzerneigene Aktien | Total Float | |
---|---|---|---|---|---|
Aktie A | 1 | 69 010 940 | 67 228 938 ( 97,42 %) | 0 | 97,42 % |
Unternehmenskontakt
aTyr Pharma, Inc.
10240 Sorrento Valley Road Suite 300
92121, San Diego
+858 731 8389
http://www.atyrpharma.comSektor
% 1. Jan. | Kap. | |
---|---|---|
+26.37% | 48.16 Mrd. | |
-1.01% | 41.73 Mrd. | |
+46.00% | 41.03 Mrd. | |
-5.31% | 28.77 Mrd. | |
+9.34% | 25.59 Mrd. | |
-21.69% | 18.96 Mrd. | |
+6.23% | 12.92 Mrd. | |
+26.99% | 12.03 Mrd. | |
-3.38% | 11.77 Mrd. |